Market Trends 4D Molecular, FDA agree on phase 3 design for DME candidateBy admin8996erT0allJanuary 10, 2025 Tamer Soliman/iStock via Getty Images4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial…
